FLFangyuan Liu

Fangyuan Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fangyuan Liu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Gang Liu

    Clinical Medicine Research Center, Affiliated Hospital of Inner Mongolia Medical University, No. 1 Tongdao North Street, Hohhot, Inner Mongolia 010050, China

    2 shared publications
  • Mengxuan Jia

    Clinical Research Center, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China

    2 shared publications
  • Xuemin Feng

    Inner Mongolia Medical University

    2 shared publications
  • Gang Liu

    Inner Mongolia Medical University

    1 shared publication
  • Liya Su

    Clinical Medicine Research Center, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, People’s Republic of China

    1 shared publication
  • Mengqi Wang

    College of Life Science and Oceanography, Weifang University, Weifang, Shandong, People’s Republic of China

    1 shared publication

Latest Publications

  • Open Access

    A transcriptomic readout of chromosomal instability reveals genome-stress states beyond proliferation in colorectal cancer

    by Fangyuan Liu, Xue Ma, Yang Guan, Mengxuan Jia, Zhiqing Yang, Xuemin Feng, Mengxue Xin, Gang Liu

    Background. Chromosomal instability (CIN) is a defining feature of colorectal cancer (CRC), yet its quantification is limited by the availability of DNA copy-number data, and most existing expression-based CIN signatures largely recapitulate proliferation. We aimed to develop and validate a DNA copy-number-anchored transcriptomic index that measures CIN itself. Methods. A DNA-level CIN_index was built in TCGA-COAD by integrating copy-number breakpoint burden, fraction of genome altered and arm-level gain/loss events (PCA). A 38-gene mRNA-CIN model was derived by WGCNA and XGBoost/Boruta feature selection with cross-validated model comparison. External validation used reference CIN/MMR phenotypes in GSE39582, GSE30540, GSE13294 and GSE18088, head-to-head comparison against CIN70 and proliferation signatures, survival meta-analysis, and pathway, immune, single-cell, DepMap and pan-cancer analyses. HCT116 cells were perturbed with the MPS1 inhibitor Reversine and assayed by flow cytometry, micronucleus staining and RNA-seq re-scoring. Results. The mRNA-CIN score recapitulated DNA-level CIN in TCGA (r = 0.750). It discriminated the reference CIN phenotype in GSE39582 (AUC 0.838, 95% CI 0.797–0.876) while CIN70 and proliferation performed at random (AUC 0.464/0.455; DeLong P = 1.6 x 10 − 28 ), tracked MSS/pMMR status across cohorts (AUC 0.83–0.90), and retained performance after proliferation adjustment. mRNA-CIN-high tumors showed replication-stress/DNA-repair programs and an immune-low phenotype reproduced across cohorts, including MSS-only tumors. The score showed no independent prognostic association (meta-analysis per-SD HR 1.02, 95% CI 0.92–1.13), supporting a measurement-tool rather than prognostic-biomarker interpretation. Single-cell and DepMap analyses resolved CIN-associated malignant epithelial states and prioritized HCT116 (low) and SW480 (high) models. Experimentally, Reversine induced dose- and time-dependent abnormal ploidy. At 48 h, micronucleus formation increased with dose, while RNA-seq showed a dose-dependent increase in the mRNA-CIN score despite suppression of CIN70 and proliferation-associated programmes. Conclusions. A copy-number-anchored 38-gene mRNA-CIN score provides a transferable transcriptomic readout of CIN-associated states across public cohorts and experimental perturbation, outperforming proliferation-based signatures. It provides a practical CIN measurement tool and a framework for selecting cellular models to study CIN-associated phenotypes and therapeutic vulnerabilities.

  • Open Access

    Theranostic Applications of Taurine-Derived Carbon Dots in Colorectal Cancer: Ferroptosis Induction and Multifaceted Antitumor Mechanisms

    by Rongrong Zhang, Shuting Lan, Mengxuan Jia, Fangyuan Liu, Mengqi Wang, Qin Jin, Liya Su, Gang Liu

    Introduction: The theranostic potential of taurine-derived carbon dots (Tau/CDs) in colorectal cancer (CRC) remains largely unexplored, despite their promising physicochemical and biological properties. Methods: In this study, Tau/CDs were synthesized via a microwave-assisted irradiation method, employing citric acid as the carbon source, urea as the nitrogen source, and taurine (Tau) as the dopant. Comprehensive physicochemical characterization and biocompatibility assessments were performed both in vitro and in vivo. The anti-cancer efficacy of Tau/CDs against CRC was systematically evaluated through a series of functional assays, including cell viability, proliferation, migration, invasion, adhesion, clonogenicity, cell cycle progression, apoptosis, epithelial-mesenchymal transition (EMT), and transcriptomic profiling. The therapeutic efficacy was further validated in vivo using CRC xenograft murine models. Results: Tau/CDs exhibited excellent biocompatibility and significantly impaired key malignant properties of CRC cells, including viability, proliferation, migration, invasion, clonogenicity, and EMT. Treatment with Tau/CDs induced cell cycle arrest and apoptosis in vitro, while in vivo administration robustly suppressed tumor growth in xenograft models. Mechanistically, transcriptomic analysis combined with ferroptosis profiling identified Heme Oxygenase 1 (HO-1)-mediated ferroptosis as a critical pathway underlying the anti-tumor activity of Tau/CDs. Conclusion: Microwave-assisted synthesis of Tau/CDs from citric acid, urea, and Tau yielded biocompatible nanoparticles with potent anti-cancer properties. Tau/CDs were shown to inhibit CRC progression by regulating multiple malignant phenotypes, with HO-1-mediated ferroptosis emerging as a critical mechanistic axis. These findings highlight Tau/CDs as a promising candidate for future clinical translation in CRC nanomedicine.